Search

Your search keyword '"De la Vega, Angela"' showing total 17 results
Start Over Author "De la Vega, Angela"
17 results on '"De la Vega, Angela"'

1. Recurrence of bile salt export pump deficiency after liver transplantation

Author

Jara, Paloma, Hierro, Loreto, Martinez-Fernandez, Pilarc, Alvarez- Doforno, Rita, Yanez, Francisca, Diaz, Maria C., Camarena, Carmen, De la Vega, Angela, Frauca, Esteban, Mufloz-Bartolo, Gema, Lopez-Santamaria, Manuel, and Larrauri, Javier; Alvarez, Luis

Subjects
Cholestasis -- Care and treatment, Jaundice, Obstructive -- Care and treatment, Liver -- Transplantation, Liver -- Patient outcomes, Children -- Health aspects, Children -- Care and treatment
Abstract

The article discusses the rare phenotypic recurrence of severe bile salt export pump (BSEP) deficiency among those patients having undergone liver transplant. The main recommendation after several studies indicates that children who are undergoing liver transplantation for BSEP deficiency should be checked for circulating anti-BSEP antibodies.

Published
2009

2. PREDICTORS OF MORTALITY AND CLINICAL CHARACTERISTICS AMONG CARBAPENEM-RESISTANT OR CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE BLOODSTREAM INFECTION IN SPANISH CHILDREN

Author

Ara Montojo, Maria Fatima, primary, Escosa Garcia, Luis, additional, Alguacil, Marina, additional, Seara, Nieves, additional, Zozaya, Carlos, additional, Plaza, Diego, additional, Schuffelmann-Gutierrez, Cristina, additional, De la Vega, Angela, additional, Fernandez-Camblor, Carlota, additional, Ramos-Boluda, Esther, additional, Romero-Gomez, Maria Pilar, additional, Ruiz-Carrascoso, Guillermo, additional, Losantos-Garcia, Itsaso, additional, Mellado, Maria Jose, additional, and Gomez-Gil, Rosa, additional

Published
2020
Full Text
View/download PDF

11. Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adult patients

Author

García-Monzón, Carmelo, primary, Jara, Paloma, additional, Fernández-Bermejo, Miguel, additional, Hierro, Loreto, additional, Frauca, Esteban, additional, Camarena, Carmen, additional, Díaz, Carmen, additional, De la Vega, Angela, additional, Larrauri, Javier, additional, García-Iglesias, Consuelo, additional, Borque, María J., additional, Sanz, Paloma, additional, García-Buey, Luisa, additional, Moreno-Monteagudo, José A., additional, and Moreno-Otero, Ricardo, additional

Published
1998
Full Text
View/download PDF

12. Our First 100 Consecutive Pediatric Liver Transplants*

Author

Vazquez, J., primary, Santamaria, M., additional, Murcia, J., additional, Gamez, M., additional, Jara, Paloma, additional, Diaz, Maria, additional, Hierro, L., additional, De La Vega, Angela, additional, Frauca, E., additional, Camarena, Carmen, additional, Goldman, L., additional, Ruza, F., additional, and Tovar, J., additional

Published
1995
Full Text
View/download PDF

13. Posttransfusion and Community‐Acquired Hepatitis C in Childhood

Author

Bortolotti, Flavia, primary, Jara, Paloma, additional, Diaz, Carmen, additional, Vajro, Pietro, additional, Hierro, Loreto, additional, Giacchino, Raffaella, additional, de la Vega, Angela, additional, Crivellaro, Carlo, additional, Camarena, Carmen, additional, Barbera, Cristiana, additional, Nebbia, Gabriella, additional, Zancan, Lucia, additional, and de Moliner, Lorena, additional

Published
1994
Full Text
View/download PDF

14. Posttransfusion and CommunityAcquired Hepatitis C in Childhood

Author

Bortolotti, Flavia, Jara, Paloma, Diaz, Carmen, Vajro, Pietro, Hierro, Loreto, Giacchino, Raffaella, de la Vega, Angela, Crivellaro, Carlo, Camarena, Carmen, Barbera, Cristiana, Nebbia, Gabriella, Zancan, Lucia, and de Moliner, Lorena

Abstract

Following a longitudinal study of chronic non-A, non-B hepatitis in Italy and Spain, we evaluated the epidemiologic and clinical features of chronic hepatitis C in 77 consecutively observed children (35 male; mean age, 4 years) without underlying systemic diseases. All subjects were positive for antibody to hepatitis C virus in serum by second-generation tests. Forty-six patients had received blood transfusions in the perinatal period; 12 had a mother with antibodies to HCV in serum (five of these mothers were drug users or partners of a drug user); seven had a history of putative percutaneous exposure; and 12 had not been exposed to any risk factors for viral hepatitis. At presentation, only 22 were symptomatic, mean alanine-aminotransferase levels were three times the upper normal value, and liver histology showed active disease in only nine of 28 cases (32). During a mean observation period of 6 years, only 11 of 57 patients (19) complained of symptoms and 11 of 40 cases (27) had histologic features of active hepatitis. Two patients had severe hepatitis with associated cirrhosis. However, only six of 57 cases (10) achieved sustained biochemical remission. The clinical features and the outcome were similar in both the posttransfusion and the community-acquired cases. These results indicate that transfusions in the perinatal period are the single most important cause of hepatitis C in otherwise healthy children. Community-acquired cases represent an heterogeneous epidemiologic group in which maternal transmission, whether perinatal or postnatal, could be relevant. Histologically severe hepatitis and cirrhosis seem to be an infrequent feature of chronic hepatitis C virus infection in childhood and adolescence, in spite of persistent liver damage.

Published
1994

16. Hepatitis C serotypes in chronic hepatitis C of children

Author

Bortolotti, Flavia, Jara, Paloma, Simmonds, Peter, Diaz, Carmen, Hierro, Loreto, Vajro, Pietro, Giacchino, Raffaella, De La Vega, Angela, Crivellaro, Carlo, Barbera, Cristiana, Camarena, Carmen, Nebbia, Gabriella, Zancan, Lucia, Frauca, Esteban, Barbierato, Emanuele, and Alberti, Alfredo

Published
1995
Full Text
View/download PDF

17. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.

Author

Jara P, Hierro L, de la Vega A, Díaz C, Camarena C, Frauca E, Miños-Bartolo G, Díez-Dorado R, de Guevara CL, Larrauri J, and Rueda M

Subjects
Adolescent, Child, Child, Preschool, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Interferon alpha-2, Interferon-alpha adverse effects, Male, Polyethylene Glycols, Recombinant Proteins, Ribavirin adverse effects, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Interferon-alpha therapeutic use, Ribavirin administration & dosage, Ribavirin therapeutic use
Abstract

Background: Interferon (IFN)-alpha2b plus ribavirin is approved for treatment of hepatitis C in children; however, little is known about efficacy and tolerability of pegylated IFN (PEG-IFN)-alpha2b in this population. The objective of this study was to test the efficacy and safety of PEG-IFN-alpha2b plus ribavirin in children with chronic hepatitis C., Methods: Thirty children 3-16 years of age who had detectable hepatitis C virus (HCV) RNA for >or=3 years after exposure and elevated alanine aminotransferase values received PEG-IFN-alpha2b 1.0 microg/kg/wk plus ribavirin 15 mg/kg/d for 24 weeks (genotype 2/3) or 48 weeks (genotype 1/4). The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA (<50 IU/mL) at week 24 of follow-up., Results: SVR was achieved in 50% of patients (3/3 genotype 3; 12/27 genotype 1/4). At week 12, 52% of patients were HCV RNA negative and 72% had a >2 log10 decrease in viral load, compared with baseline; 87% and 71% of these patients, respectively, attained an SVR. Therapy was discontinued in 3 patients as a result of adverse events. No patient required ribavirin dose reduction; PEG-IFN-alpha2b dose was reduced in 23% of patients to manage neutropenia., Conclusions: Combination therapy with PEG-IFN-alpha2b and ribavirin treatment was effective in children with chronic hepatitis C. Virologic status at week 12 identified future responders and nonresponders. PEG-IFN-alpha2b and ribavirin were reasonably well tolerated, with no unexpected or permanent adverse effects. Further studies are needed to identify the optimum treatment regimen for this patient population.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results